China Tianrui (01252) plans to issue 145 million shares for private placement, raising net proceeds of HKD 42.2 million.
China Tianrui Cement (01252) announced on December 24, 2024 that the seller Yuku Limited and...
CHINA TIANRUI (01252) announced that on December 24, 2024, Seller Yukuo Limited and the Company entered into an agreement with the placement agent, whereby the Seller conditionally agreed to appoint the placement agent (excluding all other persons) and the placement agent conditionally agreed to use its best efforts to facilitate the independent underwriter (or itself as principal) to purchase up to 145 million shares of placement shares at a price of HK$0.33 per share. Under the agreement, the Seller conditionally agreed to subscribe, and the Company also conditionally agreed to issue and allot to the Seller at the subscription price (equivalent to the placement price) an equal number of subscription shares to the placement shares.
The placement price of HK$0.33 per share represents a discount of approximately 4.35% compared to the closing market price of HK$0.35 per share on the Stock Exchange on December 24, 2024.
After deducting related costs, professional fees and actual expenses paid, the net proceeds from the subscription are estimated to be approximately HK$47 million. The net proceeds from the subscription are intended to be used as follows: approximately HK$42.2 million (approximately 89.79% of the net proceeds from the subscription) to repay part of the Company's debt; and approximately HK$4.8 million (approximately 10.21% of the net proceeds from the subscription) as general working capital for the Company.
Related Articles

CSPC PHARMA (01093): SYS6055 injection approved for clinical trials in China.

MAN SHUN GP (01746) will resume trading on January 30th after a change in ownership or a change in controlling stake.

China Railway Construction Corporation (01186) has signed new contracts with a total value of 3.076497 trillion yuan in 2025, an increase of 1.3% year-on-year.
CSPC PHARMA (01093): SYS6055 injection approved for clinical trials in China.

MAN SHUN GP (01746) will resume trading on January 30th after a change in ownership or a change in controlling stake.

China Railway Construction Corporation (01186) has signed new contracts with a total value of 3.076497 trillion yuan in 2025, an increase of 1.3% year-on-year.

RECOMMEND

Late‑Night Broad Rally As Chip Sector Receives Major Boost: Price Hikes Announced
29/01/2026

Embodied Intelligence: From Frenzy To Breakthrough Through Real‑World Deployment
29/01/2026

Dollar Falls To Four‑Year Low, Trump “Adds Fuel To The Fire”: Not Worried, Dollar Performing Well, Will Find A Reasonable Level
29/01/2026


